Guardant Health, Inc. (GH) Down 5.7% — Do I Close the Trade?
Key Points
Guardant Health, Inc. (GH) dropped 5.74% in the latest session, falling to $100.27 after shedding $6.11 from the prior close of $106.38. The stock remained under pressure throughout the day, surrendering recent gains as shares continued to face headwinds on the NASDAQ.
Trading activity leaned distinctly bearish. Volume reached 3,396,016 shares — well above the 90-day average of 2,357,897 — a clear sign that the selloff attracted heavier participation than usual. Even after the pullback, GH holds above the lower end of its 52-week range ($34.88 to $120.74), but the stock has been losing ground steadily from its peak. It now trades roughly 17% below its 52-week high of $120.74, reached on 01/22/2026, underscoring how swiftly momentum has faded since that recent high-water mark.
The day's decline also stood out against several large-cap Health Care names such as Centene (CNC), Baxter (BAX), and Elevance Health (ELV). GH's drop placed it on the weaker end of the group's typical daily swings, reinforcing the impression that the stock is sliding rather than stabilizing. With shares shedding more than $6 in a single day and turnover running elevated, the near-term tape still looks tilted toward continued selling pressure.
Why Guardant Health, Inc. Price is Moving Lower
Guardant Health's slide is notable given what looked like a headline-friendly Q4 report on Feb. 19: revenue climbed to $281.3 million (+39% year over year), and management raised FY 2026 revenue guidance to approximately $1.3 billion, ahead of consensus. The difficulty is that the market has chosen to focus on what fell short — earnings missed expectations, reinforcing concerns that growth is still being purchased with heavy spending. With a profit margin of -44.18% and EPS at -$3.21, investors appear to be discounting the quality of the top-line beat and treating the guidance raise as insufficient to alter the near-term profitability outlook.
There is also a "good news is priced in" dynamic at work. Several firms raised their targets in the days leading up to results — including JP Morgan (to $130), TD Cowen (to $135), and Baird, which initiated coverage with a $120 target — which can set a high bar for post-earnings follow-through. When a quarter fails to demonstrate clear operating leverage, traders tend to exit quickly, particularly in Health Care Equipment and Services, where reimbursement uncertainty, competitive positioning, and execution risk can shift sentiment without much warning.
On the operational side, quarterly revenue of $265.2 million shows continued momentum relative to $232.09 million in the prior quarter (+14.3%), yet the stock's weakness suggests investors are demanding stronger evidence that expanding oncology test volumes will ultimately translate into durable cash generation. Until losses narrow meaningfully, caution is warranted even in the presence of encouraging top-line trends.
What is the Guardant Health, Inc. Rating - Should I Sell?
Weiss Ratings assigns GH a D rating, with a current recommendation of Sell. The stock was upgraded on 8/15/2024, but the overall rating still signals an unfavorable risk/reward setup for investors, particularly when conditions grow less forgiving for unprofitable Health Care names.
The headline growth story has not been enough to protect shareholders. Guardant Health posts revenue growth of 38.50%, supported by a Good Growth Index and a Good Total Return Index. Yet those positives are overshadowed by a deeply negative profit margin of -44.18% and a forward P/E of -33.11, which reflects the fact that earnings remain negative. Put plainly, sales momentum has yet to translate into durable profitability, leaving the investment case exposed whenever demand softens, costs rise, or funding conditions tighten.
Weiss Ratings' sub-indices shed further light on why the overall grade remains a Sell. The Very Weak Efficiency Index is a major red flag, pointing to poor returns on capital and a business model that has yet to demonstrate it can convert growth into shareholder-friendly economics. The Weak Volatility Index compounds that concern: even for investors who find the long-term narrative compelling, the ride can be punishing, with drawdowns capable of overwhelming incremental operational progress. The Fair Solvency Index provides some balance-sheet reassurance, but it does little to offset the performance and execution risks implied by the weaker components.
Within Health Care sector, GH aligns with several pressured peers, including Centene Corporation (CNC, D) and Baxter International Inc. (BAX, E+), and sits below Elevance Health, Inc. (ELV, D+) and DexCom, Inc. (DXCM, D+). The takeaway for investors is straightforward: the upgrade provides a marginal improvement in standing, but the overall profile still leans toward underperformance risk.
About Guardant Health, Inc.
Guardant Health, Inc. (GH) is a Health Care sector company in the Health Care Equipment and Services industry focused on precision oncology. Founded in 2011 and headquartered in Palo Alto, California, the company develops and commercializes diagnostic tests and related data products designed to detect and characterize cancer using blood and tissue samples. Its core offering centers on liquid biopsy — a method that analyzes tumor-derived material circulating in blood — and it delivers testing services that support clinical decision-making and biopharmaceutical research across the United States and internationally.
Guardant Health's product lineup spans clinical testing, research tools, and software-enabled services. Guardant360 encompasses multiple configurations, including Guardant360 LDT (measuring 730+ genes), the Guardant360 CDx Test, Guardant360 Response for blood-only monitoring, and Guardant360 TissueNext for tissue-based profiling with AI-powered PD-L1 detection. For broader research and therapy development, GuardantINFINITY targets tumor molecular and immune-response complexity, while GuardantOMNI addresses advanced-stage cancer testing needs. The company also offers Guardant Reveal for adjuvant treatment and surveillance in early-stage cancer, and Shield as a screening test, backed by a Smart Liquid Biopsy Platform. Beyond assays, GuardantConnect is positioned as an integrated software solution linking tested patients with potentially relevant clinical studies, and GuardantINFORM provides an in-silico research platform focused on tumor evolution and treatment resistance. Additional offerings include companion diagnostic development, regulatory support, study operations, licensing, and kit fulfillment tied to Shield screening workflows.
Investor Outlook
With a Weiss Rating of D (Sell), Guardant Health, Inc. (GH) carries an unfavorable risk/reward profile, and investors would be well served to approach the stock with caution and tempered expectations. It is worth monitoring whether shares can hold current support levels or retest prior lows, and watching Health Care sector sentiment for any shift that could amplify volatility. Above all, keep a close eye on whether the factors driving the D grade — particularly risk-adjusted performance and balance-sheet durability — show sustained improvement. Full rankings of all D-rated Health Care stocks are available inside the Weiss Stock Screener.
--